Antiviral drug

ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme

Retrieved on: 
Monday, April 8, 2019
Health, Biotechnology, Pharmaceutical, General Health, Human orthopneumovirus, Paramyxoviridae, RSV, Nucleolin, Antiviral drug, Viruses, Branches of biology, Mononegavirales, Biology, Orthopneumovirus, Larry J. Anderson, Health, Biotechnology, Pharmaceutical, General Health

ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced that the the United States Patent and Trademark Office (USPTO) recently granted patent US10,106,539 entitled Spiro-Indolines for the Treatment and Prophylaxis of Respiratory Syncytial Virus Infection (RSV).

Key Points: 
  • ReViral Ltd., a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV), today announced that the the United States Patent and Trademark Office (USPTO) recently granted patent US10,106,539 entitled Spiro-Indolines for the Treatment and Prophylaxis of Respiratory Syncytial Virus Infection (RSV).
  • This composition of matter patent claims certain inhibitors of the fusion protein of the respiratory syncytial virus (RSV), including RV521, the Companys lead pipeline asset.
  • ReViral is progressing its lead drug candidate (RV521), a highly potent and orally bioavailable potential treatment for RSV infections.
  • ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV).

Global Hepatitis C Drugs Market Report 2019-2023: Increasing Demand for Direct-Acting Antivirals

Retrieved on: 
Friday, March 29, 2019
Infectious diseases, Chemical compounds, Medical specialties, Healthcare-associated infections, RTT, Infectious causes of cancer, Hepatitis, Antiviral drug, Biotron Limited

DUBLIN, March 29, 2019 /PRNewswire/ -- The "Global Hepatitis C Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 29, 2019 /PRNewswire/ -- The "Global Hepatitis C Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The hepatitis C drugs market to register a revenue of around USD 5.7 billion by 2023.
  • Direct-acting antiviral drugs have emerged as a curative option for patients with hepatitis C. These drugs act and block specific steps in the lifecycle of the HCV.
  • Factors such as the increasing demand for direct-acting antiviral and the increasing number of voluntary licensing agreements, will provide considerable growth opportunities to hepatitis C drugs manufactures.

Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Tuesday, March 26, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Pharmaceutical, Medical specialties, Branches of biology, Medicine, RTT, Virology, Influenza, Vaccine, Infection, Antiviral drug, Medical microbiology

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced a total of 10 upcoming presentations summarizing data on the companys lead antifungal rezafungin and its Cloudbreak antiviral program at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Key Points: 
  • Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced a total of 10 upcoming presentations summarizing data on the companys lead antifungal rezafungin and its Cloudbreak antiviral program at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
  • Our AVCs offer a fundamentally novel approach designed to provide seasonal protection from influenza, including those strains not covered by seasonal vaccines.
  • Because of their unique dual mechanism of action, our AVCs are also, unlike vaccines, expected to protect patients with compromised immune systems.
  • ECCMID convenes leading experts from around the world to present and discuss the latest research findings in infectious diseases, infection control and clinical microbiology.

SFA Therapeutics Wins Second Key U.S. Patent For Treatment of Chronic Liver Diseases

Retrieved on: 
Tuesday, March 19, 2019
Venture capital, Health, Clinical trials, Oncology, Pharmaceutical, Professional services, Medical specialties, Medicine, Infectious diseases, RTT, Immunology, Anti-inflammatory, Antiviral drug, Hepatitis, Immune system, Small molecule

SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program, which utilizes microbiome-derived metabolite small molecules as drugs to modulate the bodys anti-inflammatory and immune systems (USPTO #10,231,941).

Key Points: 
  • SFA Therapeutics today announced approval of the second key U.S. patent derived from its research & development program, which utilizes microbiome-derived metabolite small molecules as drugs to modulate the bodys anti-inflammatory and immune systems (USPTO #10,231,941).
  • Although antiviral compounds are available for patients with hepatitis B and C, nothing is available to treatmost of the other patients with chronic liver diseases.
  • Thesesmall-molecule drugs are derived fromnatural substances andenable a new platform for developing newer, safer treatmentsaimed at inflammatory diseases currently afflicting patients.
  • SFA001 has been licensed by Temple University to SFA Therapeutics in Jenkintown, PA.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190319005027/en/

FDA Accepts Genentech’s Supplemental New Drug Application for XOFLUZA (baloxavir marboxil) for the Treatment of Influenza in People at High Risk of Complications

Retrieved on: 
Wednesday, March 6, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Pharmaceutical, FDA, Chemical compounds, Organic compounds, Chemistry, RTT, Antivirals, Genentech, Baloxavir marboxil, Acetamides, Influenza A virus subtype H1N1, Influenza, Antiviral drug, Influenza vaccine

XOFLUZA is the first antiviral medicine to demonstrate a significant and clinically meaningful benefit in people at high risk of complications from the flu, for which there are currently no approved medicines.

Key Points: 
  • XOFLUZA is the first antiviral medicine to demonstrate a significant and clinically meaningful benefit in people at high risk of complications from the flu, for which there are currently no approved medicines.
  • The FDA approved XOFLUZA in October 2018 for the treatment of acute, uncomplicated influenza in people 12 years of age or older.
  • The primary objective of the study evaluated the efficacy of a single dose of XOFLUZA compared with placebo by measuring the time to improvement of influenza symptoms.
  • Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Global Antiviral Therapeutics Technologies, Markets & Companies Report 2019: 2017-2027 Estimates with Profiles of 194 Companies & 175 Collaborations

Retrieved on: 
Wednesday, February 13, 2019
Life sciences, Articles, Biotechnology, Antiviral drug, Biocides, Pharmaceutical industry in China, Biopharmaceutical

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics.

Key Points: 
  • This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics.
  • A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics.
  • Profiles of 194 companies that are involved in developing various technologies and products are profiled and with 175 collaborations.
  • These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (86), Antiviral drug companies (26) as well as viral vaccine companies (71).

Viracor Eurofins Launches Baloxavir marboxil (XOFLUZA™) Influenza A Antiviral Resistance PCR for 2019 Flu Season

Retrieved on: 
Monday, February 4, 2019
Viruses, Infectious diseases, Microbiology, RTT, Animal virology, Influenza A virus subtype H3N2, Influenza, Antiviral drug

LEE'S SUMMIT, Mo., Feb. 4, 2019 /PRNewswire/ --Today, Viracor Eurofins announces the launch of their newest antiviral resistance test, Baloxavir marboxil (XOFLUZA) Influenza A Antiviral Resistance PCR.

Key Points: 
  • LEE'S SUMMIT, Mo., Feb. 4, 2019 /PRNewswire/ --Today, Viracor Eurofins announces the launch of their newest antiviral resistance test, Baloxavir marboxil (XOFLUZA) Influenza A Antiviral Resistance PCR.
  • Identifying flu A resistance to baloxavir marboxil may be beneficial in critical and immunocompromised patients undergoing solid organ or hematopoietic cell transplants.
  • Results from clinical trials reported resistance incidences of 9-20% for H3N2 and 3-5% for H1 influenza A strains.
  • 1The New England Journal of Medicine, "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents" September 6, 2018 Vol.

Global Antiviral Therapeutic Technologies, Markets & Companies, 2019-2027: Antiviral Drugs, Vaccines, MAbs and Innovative Approaches that Include Immunological and Use of Other Technologies - ResearchAndMarkets.com

Retrieved on: 
Monday, February 4, 2019
Health, Infectious diseases, Pharmaceutical, Antiviral drug, Biocides

These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (86), Antiviral drug companies (26) as well as viral vaccine companies (71).

Key Points: 
  • These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (86), Antiviral drug companies (26) as well as viral vaccine companies (71).
  • This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics.
  • SWOT analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.
  • Although these include some of the most serious viral disorders, the development of antiviral agents for these is not commercially attractive.

Global $5.7 Billion Hepatitis C Drugs Market Forecast, 2019-2023 - Led by AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, and Merck - ResearchAndMarkets.com

Retrieved on: 
Monday, January 28, 2019
Health, Infectious diseases, Pharmaceutical, Infectious diseases, Medical specialties, Healthcare-associated infections, Medicine, RTT, Infectious causes of cancer, Hepatitis C, Hepatitis, Antiviral drug, Elbasvir/grazoprevir

The "Global Hepatitis C Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hepatitis C Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The hepatitis C drugs market to register a revenue of around USD 5.7 billion by 2023.
  • Under the voluntary licensing agreement, patent holders license others to manufacture, import, and/or distribute their patented drugs.
  • Direct-acting antiviral drugs have emerged as a curative option for patients with hepatitis C. These drugs act and block specific steps in the lifecycle of the HCV.

Nebraska, New Mexico and Kentucky Take Top Spots for State Flu Activity in this Week’s Walgreens Flu Index™

Retrieved on: 
Wednesday, January 16, 2019
Seniors, Convenience store, Women, Education, Primary, Secondary, Discount, Variety, Health, Infectious diseases, Pharmaceutical, Other Health, Baby, Maternity, Parenting, Retail, Preschool, Other Retail, Consumer, Family, General Health, MEN, Walgreens, Influenza A virus subtype H1N1, Antiviral drug, Influenza, Biology, Specialty drugs, Economy of the United States

The Walgreens Flu Index is a weekly report developed to provide state- and market-specific information regarding flu activity, and ranks those states and markets experiencing the highest incidences of influenza across the country.

Key Points: 
  • The Walgreens Flu Index is a weekly report developed to provide state- and market-specific information regarding flu activity, and ranks those states and markets experiencing the highest incidences of influenza across the country.
  • View the full release here: https://www.businesswire.com/news/home/20190116005149/en/
    Walgreens Flu Index for Week Ending January 12, 2019.
  • The Walgreens Flu Index is compiled using the drugstore chains weekly retail prescription data for antiviral medications used to treat influenza across Walgreens and Duane Reade locations nationwide.
  • In addition to the top markets and states, the Flu Index also ranks the markets and states experiencing the greatest gains in activity on a week-over-week basis.